SCHEMBL17847407

SCHEMBL17847407

CCOCOc1ccc(Br)cc1C(C)(C)C

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.57
USP2 O75604 1/20 0.43
ALPL P05186 1/20 0.43
ALOX15 P16050 1/20 0.43
ALDH1A1 P00352 1/20 0.38
TSHR P16473 3/20 0.38
HPGD P15428 2/20 0.38
GAA P10253 1/20 0.35
KMT2A Q03164 4/20 0.34
LMNA P02545 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HTT P42858 2/20 0.34
MEN1 O00255 2/20 0.34
GLA P06280 1/20 0.34
RAB9A P51151 1/20 0.34
MAPK1 P28482 1/20 0.34
S1PR4 O95977 1/20 0.34
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13748304 0.86 PTGDR2 (0.64) PTGDR2USP2ALPLALOX15ALDH1A1
SCHEMBL30006527 0.86 S1PR4 (0.46) PTGDR2USP2ALPLALOX15ALDH1A1
SCHEMBL16244453 0.83 PTGDR2 (0.60) PTGDR2USP2ALPLALOX15ALDH1A1
SCHEMBL8559282 0.83 PTGDR2 (0.54) PTGDR2USP2ALPLALOX15ALDH1A1
SCHEMBL6902107 0.82 ALDH1A1 (0.40) PTGDR2ALPLALDH1A1KMT2ALMNA
SCHEMBL7717554 0.80 PTGDR2 (0.60) PTGDR2USP2ALPLALOX15ALDH1A1
SCHEMBL17847396 0.78 TRPV4 (0.43) PTGDR2LMNAHTTMAPK1
SCHEMBL5568957 0.78 ALDH1A1 (0.44) ALOX15ALDH1A1TSHRHPGDKMT2A
SCHEMBL5564797 0.77 ALDH1A1 (0.49) PTGDR2ALDH1A1TSHRHPGDKMT2A
SCHEMBL7717609 0.76 PTGDR2 (0.56) PTGDR2USP2ALPLALOX15HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107250115-B Compounds, synthesis method thereof and application thereof in medicines and cosmetics 盖尔德马研究及发展公司 2021-11-05 CN disclosed
EP-3233806-B1 HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS GALDERMA RES & DEV (FR) 2021-10-27 EP disclosed
US-10647688-B2 Compounds, synthesis method thereof and use of same in medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2020-05-12 US disclosed
US-20170342040-A1 NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-11-30 US disclosed
EP-3233806-A1 NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS Galderma Research & Development (FR) 2017-10-25 EP disclosed
WO-2016097626-A1 NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342040-A1 NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS RARA, RARB, RARG PTGDR2 225/4885USP2 3155/4885ALPL 2173/4885
US-10647688-B2 Compounds, synthesis method thereof and use of same in medicine and in cosmetics RARA, RARB, RARG PTGDR2 224/4885USP2 3241/4885ALPL 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.